Additionally, recurrent HCC showed a higher proportion of PD-L1+ malignant cells than primary HCC, and competitive binding of PD-L1 to CD80 inhibited antigen presentation which further led to compromised anti-tumor immunity (19). This evidence concerns the gene CD80 and neoplasm.